CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Windtree Therapeutics, Inc. - WINT CFD

0.3651
5.17%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0262
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.385
Open 0.3719
1-Year Change -48.31%
Day's Range 0.3611 - 0.3805
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 0.3651 -0.0025 -0.68% 0.3676 0.3830 0.3504
Dec 16, 2024 0.3850 0.0351 10.03% 0.3499 0.4099 0.3323
Dec 13, 2024 0.3291 -0.0161 -4.66% 0.3452 0.3541 0.3291
Dec 12, 2024 0.3551 0.0090 2.60% 0.3461 0.3551 0.3195
Dec 11, 2024 0.3486 -0.0165 -4.52% 0.3651 0.3651 0.3290
Dec 10, 2024 0.3585 0.0010 0.28% 0.3575 0.3725 0.3465
Dec 9, 2024 0.3565 0.0045 1.28% 0.3520 0.3765 0.3465
Dec 6, 2024 0.3603 -0.0247 -6.42% 0.3850 0.3872 0.3395
Dec 5, 2024 0.3750 -0.0100 -2.60% 0.3850 0.4049 0.3399
Dec 4, 2024 0.4140 -0.0641 -13.41% 0.4781 0.5000 0.4003
Dec 3, 2024 0.4953 -0.0461 -8.51% 0.5414 0.5414 0.4953
Dec 2, 2024 0.5377 0.0052 0.98% 0.5325 0.5490 0.5224
Nov 29, 2024 0.5234 -0.0431 -7.61% 0.5665 0.5941 0.4547
Nov 27, 2024 0.5570 0.0156 2.88% 0.5414 0.6066 0.5162
Nov 26, 2024 0.5191 -0.0352 -6.35% 0.5543 0.5543 0.5019
Nov 25, 2024 0.5438 0.0443 8.87% 0.4995 0.5438 0.4763
Nov 22, 2024 0.4715 0.0000 0.00% 0.4715 0.4991 0.4715
Nov 21, 2024 0.4936 -0.0179 -3.50% 0.5115 0.5126 0.4620
Nov 20, 2024 0.4727 0.0080 1.72% 0.4647 0.5069 0.4411
Nov 19, 2024 0.4430 -0.0382 -7.94% 0.4812 0.4812 0.4430

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Windtree Therapeutics Inc. Company profile

About Windtree Therapeutics Inc

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and acute pulmonary diseases. The Company’s cardiovascular programs includes Istaroxime (Early Cardiogenic Shock), Istaroxime (acute heart failure), Rostafuroxin and Oral SERCA2a Activators. Its Pulmonary Programs include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on Aerosol Delivery System technology). The Company’s subsidiaries Discovery Laboratories, Inc., CVie Investments Limited and CVie Therapeutics Limited.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Windtree Therapeutics Inc revenues was not reported. Net loss increased from $25.1M to $54.6M. Higher net loss reflects Research and development - Balancing val increase of 8% to $11.1M (expense), Stock-based Compensation in R and D increase of 39% to $2.3M (expense), Stock-based Compensation in SGA increase of 21% to $3.4M (expense).

Equity composition

Common Stock $.015 Par, 04/11, 50M auth., 13,822,000 issd., less 21,000 shs. in Treas. @ $3.1M. Insiders own 1.88%. *NOTE: 12/97 Name changed from Ansan Pharmaceuticals; FY'00 Qs are restated. *2/05, PO 5.06M shares @ $5.75 by SG Cowen & Co., LLC. 12/10, 1-for-15 reverse split. 01/06, 1-for-14 reverse stock split

Industry: Biotechnology & Medical Research (NEC)

2600 Kelly Rd Ste 100
WARRINGTON
PENNSYLVANIA 18976-3652
US

People also watch

BTC/USD

104,972.70 Price
-1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,644.96 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0055%
Short position overnight fee -0.0027%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

22,032.80 Price
+0.280% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

ETH/USD

3,866.61 Price
-1.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading